Abstract Many cellular cofactors have been documented to be critical for various stages of viral replication. Using highthroughput proteomic assays, we have previously identified Bruton's tyrosine kinase (BTK) as a host protein that was uniquely upregulated in the plasma membrane of human immunodeficiency virus (HIV-1)-infected T cells. Here, we have further characterized the BTK expression in HIV-1 infection and show that this cellular factor is specifically expressed in infected myeloid cells. Significant upregulation of the phosphorylated form of BTK was observed in infected cells. Using size exclusion chromatography, we found BTK to be virtually absent in the uninfected U937 cells; however, new BTK protein complexes were identified and distributed in both high molecular weight (∼600 kDa) and a small molecular weight complex (∼60-120 kDa) in the infected U1 cells. BTK levels were highest in cells either chronically expressing virus or induced/infected myeloid cells and that BTK translocated to the membrane following induction of the infected cells. BTK knockdown in HIV-1-infected cells using small interfering RNA (siRNA) resulted in selective death of infected, but not uninfected, cells. Using BTK-specific antibody and smallmolecule inhibitors including LFM-A13 and a FDAapproved compound, ibrutinib (PCI-32765), we have found that HIV-1-infected cells are sensitive to apoptotic cell death and result in a decrease in virus production. Overall, our data suggests that HIV-1-infected cells are sensitive to treatments targeting BTK expressed in infected cells.
Introduction
The human immunodeficiency virus (HIV-1) is the causative agent of acquired immunodeficiency syndrome (AIDS) that infected more than 35 million people worldwide (UNAIDS Report 2013) . Despite the success of combined antiretroviral therapy (cART) in treating HIV-1 infection and preventing progression to AIDS (Bagasra 2006; Chun et al. 1999; Cohen 2005; Jordan et al. 2003) , limitations include the generation of resistant viral strains. Moreover, even though the cART is efficient in eradicating the circulating virus in plasma by inhibiting productive infection, the cART is not able to completely inhibit virus production from the infected cells (Richman et al. 2009 ). HIV-1 is capable of maintaining latent infection in reservoirs such as resting CD4+ memory and Irene Guendel and Sergey Iordanskiy contributed equally to this work.
naive T cells, myeloid cells, and CD34+ multipotent hematopoietic stem cells (Carter et al. 2010; Cobos-Jimenez et al. 2011; Evans et al. 2013; Gougeon et al. 2012; Wightman et al. 2010) . Thus, the identification of new markers of nonproductive HIV-1 infection as well as determination of the new potential targets for therapeutic interventions are the critical tasks of the current HIV/AIDS research.
Using comparative proteomics analysis, we have previously identified the Bruton's tyrosine kinase (BTK) as one of the 17 candidate proteins unique to latent HIV-1-infected T cells, where BTK was localized to the cytoplasm and translocated to the plasma membrane upon viral activation (Berro et al. 2007) . BTK is a member of the Tec family of nonreceptor protein tyrosine kinases and is encompassed within the Src superfamily, an important regulator of lymphocyte signaling (Berg et al. 2005; Mano 1999) . BTK is structurally characterized to contain the Src homology-1 (SH1) tyrosine kinase domain and additional protein-protein interaction domains SH2 and SH3 (Lindvall et al. 2005) . Moreover, it harbors a pleckstrin homology (PH) domain located at the N-terminus which permits PH domain-mediated BTK translocation to the plasma membrane (Mohamed et al. 1999; Salim et al. 1996; Varnai et al. 1999) . BTK characterization studies have been mostly performed in B cells, where it has been shown to influence multiple signaling pathways including calcium influx, cytoskeletal remodeling, apoptosis, survival, proliferation, differentiation, and gene expression (Contreras et al. 2007; Fluckiger et al. 1998; Liu et al. 2011; Matsuda et al. 2009; Satterthwaite et al. 1998; Uckun 1998) . Of interest, BTK has been shown to play a dual role in cell survival and apoptosis in a cell type-specific manner, conferring an anti-apoptotic effect in B cells while promoting apoptosis in HeLa cells (Islam and Smith 2000; Uckun 1998) . BTK is primarily a cytoplasmic enzyme but can be recruited to the plasma membrane as a result of phosphoinositide 3-kinase (PI3K) activation in a PI3K-dependent manner (Mohamed et al. 1999; Mohamed et al. 2000; Salim et al. 1996; Scharenberg and Kinet 1998; Varnai et al. 1999) . PH-mediated membrane recruitment occurs through binding to phosphatidylinositol-3,4,5-trisphosphate (PIP 3 ) after PI3K activation. BTK is required for proper tyrosine phosphorylation and activation of phospholipase C-γ (PLC-γ) which catalyzes the formation of inositol-3-4-5 triphosphate (IP 3 ) and diacylglycerol, which in turn mediate calcium mobilization and activation of protein kinase C (PKC), respectively . The IP 3 and PKC pathways lead to activation of transcription factors such as NF-κB, BAP-135, and TFII-I that regulate gene expression required for B cell survival and cell cycle progression (Bajpai et al. 2000; Novina et al. 1999; Petro et al. 2000; Yang and Desiderio 1997) . In addition to a cytoplasmic and membrane location, BTK was also found in the nucleus (Mohamed et al. 2000; Saito et al. 2003; Webb et al. 2000b ). Regulation of the nuclear translocation of this protein remains to be explored. However, a recent study showed that BTK nucleocytoplasmic shuttling requires its interaction with Lyn-interacting ankyrin repeat (Liar) protein, utilizing a Crm1-mediated mechanism of nuclear export (Gustafsson et al. 2012) .
In the present study, we have characterized the expression profiles of BTK in different chronically HIV-1-infected cells including monocytes/macrophages. We demonstrate that BTK is upregulated during HIV-1 replication. Relevant to the BTK membrane translocation and nuclear shuttling activities observed earlier in B cells, we show that treatment with the PI3K inhibitors LY294002 and wortmannin in the presence of activated HIV-1 leads to decreased BTK translocation to the plasma membrane (Berro et al. 2007 ). We also show that selective depletion or inhibition of BTK kinase activity results in apoptosis of infected, but not uninfected, cells. Taken together, our results suggest that viral regulation of receptor signaling can be mediated by redistribution of cytoplasmic and probably nuclear BTK to the cell membrane. Since BTK inactivation leads to selective apoptosis of HIV-1-infected cells, targeting the host BTK pathway could potentially serve as an attractive host-based therapeutic strategy for the elimination of latent HIV-1 infection.
Results

BTK expression is induced in HIV-1-infected cells
Using membrane proteomics analysis of HIV-1-infected T cells, we have previously identified that among other proteins, BTK is upregulated in infected cells (Berro et al. 2007) . In order to further explore the BTK expression profile during infection, Western blot was performed in various cell types including uninfected (CEM and Jurkat) and HIV-1-infected T cells (positive control; ACH2 and J1.1), matched uninfected and infected monocytic cells (U937 and U1), and phorbol-12-myristate-13-acetate (PMA)-activated U937 and U1 cells that are considered as a model of monocyte-derived macrophages (MDM model: U937 mФ/U1 mФ). The B cell line (BJAB) was used as a positive control for BTK expression. Results shown in Fig. 1a indicate that BTK levels are much higher in the HIV-1-infected cells when compared to the uninfected counterparts for T cells, monocytes, and MDM model cells. These results further show selective upregulation of BTK across a panel of cell lines that are chronically infected with HIV-1. To further examine BTK upregulation during de novo infection, we transfected the infectious HIV-1 clone pNL4.3 into Jurkat T cells (control) and monocytic U937 cells and assessed the BTK distribution status by Western blot. Results in Fig. 1b indicate that there is significant upregulation of BTK expression at 48 h post-infection (lane 2) when compared to mock-treated cells (lane 1). Even though BTK expression was detectable in both uninfected T and monocytic cells, we observed significant upregulation of the phosphorylated form of BTK in all infected cells including both chronically (Fig. 1a) and newly (Fig. 1b) infected cell lines. Previously, we have shown in a latency model that increased BTK phosphorylation may be linked to its HIV-1-specific translocation and enrichment at the plasma membrane, where it becomes further phosphorylated (Berro et al. 2007 ). Finally, we were interested in exploring whether BTK localization was differently affected in HIV-1-infected cells. The Western blot of cytoplasmic versus nuclear extracts, shown in Fig. 1c , revealed that BTK levels were increased in infection both at the cytoplasmic and nuclear fractions (lanes 2 and 4) when compared to uninfected fractions (lanes 1 and 3). Interestingly, BTK found in the cytoplasm of infected cells was mainly phosphorylated, whereas both phosphorylated and unphosphorylated forms of BTK were present in the nucleus. In contrast, BTK is found mainly in the nucleus of uninfected Fig. 1 BTK expression is induced in HIV-1-infected cells. a To assess BTK expression in a series of HIV-1-matched cell targets, 50 μg of whole cell extracts from B cells (BJAB), uninfected T cells (CEM and Jurkat), uninfected monocytic cells (U937 and U937-derived macrophage model cells, mФ), HIV-1-infected T cells (ACH2 and J1.1), and infected monocytic cells (U1 and U1 mФ) were run on a 4-20 % SDS-PAGE and immunoblotted against BTK and β-actin. b Jurkat and U937 cells were transfected with the HIV-1 clone pNL4-3 using Effectene transfection reagent, harvested at 48 h, and lysed in Laemmli sample buffer. Twenty micrograms of whole cell extract was assayed by Western blot using α-BTK and α-β-actin antibodies. Phosphorylated BTK (p-BTK) is suggestive of BTK activation. c Cytosolic and nuclear extracts were prepared from Jurkat and J1.1 cells as described in BMaterials and methods.^The extracts were analyzed by Western blot using anti-BTK antibody. Lamin A was used as a nuclear control. d Total cell lysates of both uninfected U937 and infected U1 cells were loaded onto a size-exclusion chromatography column and proteins separated in the presence of high-salt buffer (500 mM NaCl) to minimize nonspecific binding. No detergent was used during fractionation. A sampling (250 μl) of every fifth fraction from 10-55 was acetone precipitated and resuspended in 30 μl of Laemmli buffer, and then 15 μl was run on a gel for Western blotting using BTK and β-actin antibody. More soluble actin was present in the U1 fractions as compared to uninfected U937 cells cells in an unphosphorylated form, with little to no BTK detectable in the cytoplasm. Thus, increased phosphorylation in de novo infection may be indicative of increased BTK activation and possible translocation to the plasma membrane where it partakes in the BTK signalosome, modulating signal transduction in a pro-or anti-apoptotic pathway (Islam and Smith 2000) .
We finally asked whether BTK-associated complexes could be modified between infected and uninfected cells. Our rationale came from our previous work where complexes such as Cdk9/T1 complex, GSK, and IKK were present in both large and small complexes after infection Kehn-Hall et al. 2011; Narayanan et al. 2012) . Importantly, these novel small complexes were highly kinase active and were formed only after infection. Here, we used total cell lysates of both uninfected U937 and infected U1 cells and loaded onto a sizing column in the presence of high salt to minimize nonspecific binding (500 mM NaCl). FPLC fractions were then precipitated and used for Western blot analysis. Results of such an experiment are shown in Fig. 1d , where BTK was virtually absent in the uninfected U937 cells; however, the BTK protein complexes were distributed in both high molecular weight (∼600 kDa) and a small molecular weight (∼60-120 kDa, possibly the phosphorylated form) complex in the infected U1 cells. We also observed more actin distribution in the U1-infected cells compared to uninfected cells. The initial loading of actin onto the column was similar between infected and uninfected cells (lane 1). These data on distribution of BTK between large and small complexes further indicate that infection may cause a distribution between both active and inactive forms of BTK in cell.
Presence of BTK on the cell surface membrane
We next examined the presence of BTK protein on both chronically infected and latent cells. We used J1-1 cells (Jurkat T cell background) where a wild type virus is secreted into the media from these cells and compared to U1 cells, which contain two copies of silent viruses (one wild type and one mutant). In both cases, cells were grown to mid-log phase of growth and stained with BTK antibody, without any fixation. We also used U937 as control cells for infected U1 cells either with or without PMA treatment. Results in Fig. 2a show that J1-1 cells (which actively secrete virus) have an approximately fivefold induction and presence of BTK on the membrane. Interestingly, U1 myeloid cells that do not secrete virus had minimal BTK on the surface, but upon activation, BTK levels increased by about fivefold (panel C) as compared to just a 70 % increase for uninfected U937 cells. It is interesting to note that even though U1 cells contained higher levels of BTK protein, as determined by sizing column and Western blots (Fig. 1a, d) , most of the protein becomes membrane associated after viral induction. Collectively, these results indicate that the BTK levels were highest in cells either chronically expressing virus or induced/infected myeloid cells and that BTK translocates to the membrane following induction of the infected cells.
Selective BTK depletion induces apoptosis
Due to the dual role of BTK regarding apoptosis, we were interested to determine if inhibiting BTK expression through small interfering RNA (siRNA) knockdown would have an effect on cell survival. The HLM-1 cells (Sadaie et al. 1990) were transfected with two siRNAs against BTK (BTK #1 and BTK #2) and cultured for 24, 48, and 72 h post-transfection. In the absence of induction, the HLM-1 cell line is negative for virus particle production but displays basal transcription (i.e., latent phenotype). Small interfering RNA against luciferase was used as a negative control. Results in Fig. 3a indicate that BTK #1 siRNA transiently but dramatically decreased the presence of phosphorylated BTK at 24 and 48 h post-transfection, respectively (lanes 4 and 5), while BTK #2 siRNA decreased the level of this BTK form only at 24 h (lane 7). The nonphosphorylated BTK was detected as a minor form of this enzyme in these cells. To evaluate if loss of BTK resulted in apoptosis in these cells, we performed Western blot analysis against caspase 3 and poly(ADP-ribose) polymerase (PARP), canonical markers of the apoptotic cascade activation. The activation of caspase 3 leads to downstream cleavage events of cytoplasmic and nuclear substrates including PARP, attributing morphological features of apoptotic cell death (Huppertz et al. 1999) . Results in Fig. 3b indicate that upon BTKselective depletion, cleavage of both procaspase-3 and PARP was observed (lanes 2-3 and 5-6) in contrast to their respective luciferase control samples (lanes 1 and 4) or when the RNA interference (RNAi)-mediated knockdown had resolved at 72 h post-transfection (lanes 8-9). As a further confirmation, we then treated HLM-1 cells with either siRNA and performed a cell viability assay. Results in Fig. 3c indicate that either siRNA was capable of inhibiting or apoptosing cell growth after 72 h of treatment. Taken together, these data indicate that selective downregulation of BTK, and especially the phosphorylated form of this enzyme, triggers programmed cell death pathways, suggesting that BTK may play an antiapoptotic role in HIV-1-infected cells.
Treatment with BTK antibody results in selective death of HIV-1-infected cells Monoclonal antibodies against plasma membrane proteins that are overexpressed in cancer cells, such as VEGF and EGFR, have been successfully used as targeted therapeutics (Ludwig et al. 2003) . In the case of HIV-1 infection, there are currently two humanized monoclonal antibodies for CCR5, Pro-140 and HGS Ab004, which inhibit viral entry (Castagna et al. 2005; Lederman et al. 2006) and are in clinical trials. Since BTK localizes specifically to the plasma membrane of HIV-1-infected cells, we tested whether antibody treatment against BTK could induce cell death in HIV-1-infected cell lines. A variety of uninfected and infected cell lines were incubated with a titration of monoclonal BTK antibody or IgG as a nonspecific target control. Twenty-four hours post-treatment, trypan blue staining and CellTiter-Glo assays were used to assess cellular viability or growth. Results in Fig. 4a depict a panel of cells treated with α-BTK antibodies and control IgG for 24 h. Infected T cells (control; ACH2 and J1.1) and monocytes (U1) displayed >35 % loss of cell viability upon treatment with BTK antibody, whereas corresponding uninfected cells were largely unaffected by the treatment. Similarly, reproduction of these results in uninfected Jurkat and infected J1.1 cells indicated a preferential decrease in viability of the HIV-1-infected cells upon exposure to α-BTK antibody (Fig. 4b) . Moreover, to confirm these observations in an inducible system, the activation of viral replication in HLM-1 cells was stimulated with the HDAC inhibitor sodium butyrate (NaB) for 72 h prior to treatment with BTK antibody. Results in Fig. 4c indicate that at 48 h post-treatment, cells which had undergone viral induction were more susceptible to selective BTK antibody cell killing. We have previously shown that viral induction in HLM-1 cells results in virus-specific translocation of BTK to the plasma membrane (Berro et al. 2007) . These data suggest a feasible correlation between BTK localization in the presence of active HIV-1 and susceptibility to therapeutic targeting of BTK.
We have previously identified the anti-apoptotic protein Xlinked inhibitor of apoptosis (XIAP) as one of the proteins enriched in the membrane fractions of latently infected cells (Berro et al. 2007 ). To further test the effect of BTK antibody on infected cells, we subjected U937 and U1 MDM cell models to treatment with antibodies against BTK and XIAP. Antibody treatment against CD45 was used as a positive control for macrophage-specific induced cell death (Steff et al. 2003) . Six days post-treatment, we tested the effect of antibodies on cell viability by using CellTiter-Glo assay. Results in Fig. 4d indicate that treatment with anti-CD45 antibody effectively induced cell death in both uninfected (92 % cell death) and infected cells (96 % cell death). Furthermore, BTK show baseline expression of surface BTK levels prior to differentiation with PMA treatment and an increase of 70 % following PMA treatment. c Latently infected U1 cells (experimental) were used for staining with BTK antibodies. These cells do not normally express virus; however, after the addition of PMA, they are differentiated to macrophages and express virus. These cells show low basal BTK surface staining and an approximately fivefold increase of BTK upon PMA stimulation antibody treatment resulted in decreased viability only in the infected U1 MDM cell model (87 % cell death). Interestingly, XIAP antibody treatment did not induce cell death in either U937 or U1 MDMs, suggesting that the regulatory mechanism of cell apoptosis exerted by HIV-1 via XIAP is different from that of BTK. Collectively, these results indicate that HIV-1-infected cells are more sensitive to BTK antibody treatment possibly due to the specific upregulation of BTK in infected cells.
BTK antibody treatment results in decreased HIV-1 viral replication
Therapeutic approaches that result in the killing of infected cells may affect release of immature viral particles into the extracellular space or maturation of the virions. Therefore, we next asked whether the treatment of infected cells with α-BTK antibody could modulate viral release after triggering cell death. Our rationale for these experiments came from previous findings that certain treatments that stimulate apoptosis may both decrease or increase viral replication. For instance, our earlier study showed that irradiation of chronically infected cells increases apoptosis but also simultaneously activates cells and induces viral replication and release (Clark et al. 2000) . We treated both HLM-1 cells that have undergone viral activation and the chronically infected J1.1 T cells that produce HIV-1 without additional activation with either α-BTK antibody or control IgG. Antibody treatment was performed once and supernatants were collected 2 days post-treatment for reverse transcriptase (RT) activity. Results in Fig. 5a indicate that BTK antibody treatment inhibited viral replication in HLM-1 cells. Likewise, α-BTK also decreased RT activity in the supernatant from chronically infected J1.1 cells (panel B). Finally, we asked whether genomic RNA levels also decreased following antibody treatment. Experiments in panel A and B used reverse transcriptase protein as a readout of the functional viral particles in the supernatant; however, unspliced RNA molecules were not assayed following antibody treatment. Experiments in panels C and D using both HLM-1 and J1-1 cells showed reduced levels of genomic RNA following /ml) were transfected with either siLuc or siBTK (10 nm) using Effectene. Cells were harvested at 24, 48, and 72 h post-transfection, and 20 μg of whole cell lysates was resolved by SDS-PAGE and immunoblotted against BTK to assay for effective siRNA-mediated BTK downregulation. b Similar to a, where cell lysates were further probed with α-caspase 3 and α-PARP antibodies as markers of programmed cell death. Western blots against β-actin were performed as a loading control. c Similar to a, where HLM-1 cells were transfected with siLuc, siBTK #1, and siBTK #2 (50 nM). Viability was assessed using CellTiter-Glo assay 72 h post-treatment. Results are shown as the mean of three independent experiments±SD BTK antibody treatment. Interestingly, IgG treatment showed an increase of viral RNA levels but not RT activity in the supernatants, indicating that IgG alone could increase RNA levels, but not functional virus. Taken together, these results suggest that BTK antibody treatment selectively induces apoptosis in infected cells and also decreases viral shedding from these cells.
BTK antibody treatment induces cell death in HIV-1-infected PBMCs
To determine whether BTK antibody treatment had an effect on primary cells, we infected PHA/IL-2-activated peripheral blood mononuclear cells (PBMCs) with the dual tropic HIV-1 89.6 virus and subsequently treated once with either BTK Fig. 4 BTK antibody treatment induces cell death in HIV-1-infected, but not uninfected, cells. a Uninfected cells (CEM and U937) and HIV-1-infected cells (ACH2, J1.1, and U1) were treated with 5 μg/ml of IgG as a control or two concentrations of anti-BTK antibody (1 and 5 μg/ml). Cell viability was determined by trypan blue dye exclusion cell quantitation (100 cells per sample) at 24 h post-treatment. BTK antibody treatment decreased viability when compared to the respective uninfected controls by 36 % in ACH2 cells, 59 % in J1.1 cells, and 58 % in U1 cells at 5 μg/ml. b Jurkat (uninfected) and J1.1 chronically HIV-1-infected cells were treated with 1 μg/ml of IgG or antibody against BTK. Viability was assessed using CellTiter-Glo assay 48 h post-treatment. Error bars show the standard deviation of three independent measurements. c Latently HIV-1-infected HLM-1 cells were activated with 2 mM sodium butyrate (NaB) for 72 h followed by treatment with 5 μg/ml of BTK antibody. Cells were subjected to CellTiter-Glo viability assay at 48 h post-treatment. Results are the mean ± SD of three independent preparations. d Uninfected monocytic control cell line U937 and latently HIV-1-infected U1 cells were subjected to differentiation with 250 nM PMA for 96 h. The monocyte-derived macrophages (U937 mФ and U1 mФ) were treated with 10 μg/ml of α-BTK and α-XIAP antibodies. The α-CD45 antibody was used as a positive control for receptor-mediated macrophage cell death. Cells were subjected to CellTiter-Glo viability assays at 48 h post-treatment. Treatments were performed in triplicate and the mean±standard deviation is displayed. The double asterisks indicate p≤0.01. Viability is expressed as percent of IgG control antibody or control IgG. Uninfected PBMCs were also treated in parallel as controls. On day 10, cells were stained with propidium iodide and analyzed by flow cytometry to determine whether antibody treatment resulted in alteration of the cell cycle or induction of apoptosis. Results in Fig. 6a show that the treatment with BTK antibody induced substantial apoptosis (73.78 %) in infected PBMCs (upper panel), while the uninfected PBMCs remained unaffected (3.97 % apoptosis, lower panel). Interestingly, antibody-mediated suppression of membrane-localized BTK resulted in complete death of the cells in G 0 /G 1 and G 2 /M stages of the cell cycle, whereas the cells with replicating DNA in the S phase of the cell cycle remained viable (Fig. 6b) , suggesting either reduced exposure of BTK on the plasma membrane of these cells or that the BTK activity is not essential for viability of the cells in the S phase. Earlier studies of cancer cells treated with the BTK inhibitor LFM-A13 have been reported to exhibit a G 2 /M arrest during cell cycle progression and lower level of cell death (Uckun 2007) , indicating that stronger pro-apoptotic effect in our experiment could be associated with HIV-1 activation. Collectively, the present data indicate that targeting BTK may result in death of HIV-1-infected primary cells. In addition, these data further suggest that BTK antibody treatment does not exhibit apparent toxicity to uninfected primary cells.
The BTK inhibitor LFM-A13 and ibrutinib induce cell death in HIV-1-infected, but not in uninfected, cells
In addition to therapeutic effects observed by monoclonal α-BTK antibody treatment on HIV-1-infected cells, we were interested in exploring treatment effects with commercially available small-molecule inhibitors such as alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide or LFM-A13. LFM-A13 is a leflunomide metabolite analog designed to target the TEC family protein tyrosine kinase BTK (Mahajan et al. 1999; Uckun et al. 2003) . To determine the effect of the specific pharmacological BTK inhibitor LFM-A13 on cell viability, uninfected CEM and Jurkat and HIV-1 chronically infected T cells, alongside the uninfected Similar to a and b, except that the supernatants were assayed for presence of viral particle, using qRT/PCR for unspliced HIV-1 RNA. HLM-1 cells were treated with sodium butyrate for 72 h to activate the latent HIV-1 provirus. Results are the mean±SD of three independent preparations. Single asterisk indicates p≤0.01, and double asterisks p≤0.05 monocytic U937 and infected U1 cells, were subjected to LFM-A13 or vehicle for 72 h. Results in Fig. 7a show that LFM-A13 decreased cell viability in a dose-dependent manner in HIV-1-infected cells when compared to DMSO-treated cells. BTK was originally identified in B cells, and it has been found more recently in myeloid cells, including monocytes, macrophages, neutrophils, and mast cells (Mohamed et al. 2009 ). Thus, the BJAB B cell line was used as a positive .1, and U1) and uninfected (CEM, Jurkat, and U937) cells was treated with 10, 50, or 100 μM of LFM-A13 for 72 h. BJAB served as positive control. Viability was assessed by CellTiter-Glo assay as described by the manufacturer. Treatments were performed in triplicate and the mean±SD is presented. The asterisks indicate p≤0.05. Viability is expressed as percent of DMSO control. b Latently HIV-1-infected ACH2 cells were similarly treated with the above concentrations of LFM-A13 for 72 h. Supernatants were collected at day 3 for RT activity analysis. Treatments were performed in triplicate and the mean±SD of three representative experiments is provided. RT activity is expressed as percent of DMSO control. c Uninfected B cells (BJAB, lanes 1-4), uninfected CEM T cells (lanes 5-8), and infected cells (ACH2, lanes 9-12) were treated with either DMSO or ibrutinib (10, 50, or 100 nM) for 72 h. Cell deaths following drug treatments were monitored by comparing the levels of luminescence with DMSO treatment. Results are the mean±SD of three independent measurements. Single asterisk indicates p≤0.05. d Infected cells (ACH2) were treated with either DMSO, LFM-A13 (10, 50, or 100 μM), or ibrutinib (10, 50, or 100 nM) for 48 h. The supernatants were assayed for presence of viral particle, using qRT/PCR for unspliced HIV-1 RNA. Results are the mean ± SD of three independent preparations. The asterisks indicate p≤0.01 activity for the viability of HIV-1-infected, but not uninfected, cells. Interestingly, we observed the strongest effect of BTK inhibition on the cell viability in the ACH2 and U1 HIV-1-infected cells, which produce minimal amount of HIV-1 particles (Clark et al. 2000) , whereas the effect of LFM-A13 was minimal on the J1.1 cells that persistently produce higher amounts of HIV-1 virions without activation.
To complement the effects of LFM-A13 observed on the infected cells, we explored its effect on the viral replication. LFM-A13 treatment was performed once on infected cells, and supernatants were collected at day 3 for RT analysis. Results in Fig. 7b indicate that LFM-A13 triggers a dosedependent decrease of viral replication in infected cells. These results are consistent with anti-BTK antibody treatment (Figs. 4 and 5) where BTK inhibition also induced death of HIV-1-infected cells and simultaneous decrease of viral production. We next utilized another BTK inhibitor, ibrutinib (PCI-32765), that was in a phase III clinical trial for treatment of chronic lymphocytic leukemia (CLL) and recently approved by the FDA. We treated infected and uninfected cells with three concentrations of ibrutinib for 24 and 48 h. Results in Fig. 7c indicate that HIV-1-infected cells were very sensitive to ibrutinib as evident by the increased apoptosis. Similar to LFM-A13, ibrutinib showed a decrease in the intracellular p24 expression (using Western blot) by more than 90 % in infected cells (data not shown). Finally, we compared both LFM-A13 and ibrutinib side by side in cells and looked for the presence of HIV-1 genomic RNA. Results in panel D indicate that both LFM-A13 and ibrutinib inhibited genomic RNA present in the supernatants of infected cells in a dosedependent manner. Collectively, these data point to the use of various BTK inhibitor drugs as an alternative means of cell killing in infected cells.
Target of BTK inhibitor in infected cells
To characterize the putative mechanisms by which LFM-A13 could exert its effects on HIV-1-infected cells, we analyzed uninfected and chronically infected cells by reverse phase protein microarray (RPMA) technology. Cells were treated with LFM-A13 or DMSO for 24 h prior to preparation of the cell lysate. For phosphoproteomic analysis, cell lysates were immobilized by printing onto nitrocellulose membrane slides and probed with antibodies specific for phosphorylated or total forms of signaling proteins. The antibodies were selected to screen molecular networks involved in host responses believed to be affected by viral infection, specifically immune response, cell survival and apoptosis, inflammation and cell growth, and differentiation. RPMA has been extensively validated in previous studies regarding antibody specificity, sensitivity, and accuracy of phosphoprotein detection in cell lysates (Wulfkuhle et al. 2006) . Moreover, RPMA has been recently used to characterize the phosphoproteome and signaling networks induced by Rift Valley fever virus infection (Popova et al. 2010) . Table 1 shows a summary of significant changes in signal transduction upon LFM-A13 treatment of infected cells. Changes in protein expression were normalized to DMSO-treated infected and LFM-A13-treated uninfected cells. To map these signaling pathways and discover important signaling pathway nodes mediated by LFM-A13, we annotated a narrow protein-protein interaction network (Fig. 8) . Although PI3K was not identified as a LFM-A13-responsive node, it is functionally linked to the BTK signalosome and subsequent effector proteins. As shown in the signaling pathways, tyrosine kinases PI3K/AKT cascade; effector kinases serine/threonine GSK-3β and Aurora; p90RSK; substrates BAD, MDM2, c-Myc, and mTOR; and microtubule dynamics-associated protein LC3B were involved in the LFM-A13-mediated phosphorylation signaling pathways. Taken together, these data demonstrate that the BTK inhibitor LFM-A13 induces cell death in HIV-1-infected cells, suggesting that the cell death is induced largely through modulation of the PI3K/AKT signaling network.
Discussion
Current cART uses selective inhibitors that target only viral proteins. Novel targeted host-based therapies serve as an attractive approach for the development of new treatment alternatives as well as to advance the understanding of disease mechanisms. In this study, we have further characterized BTK as a cellular factor important for HIV-1 replication and viability of infected cells. The demonstrated role of BTK in HIV-1 infection along with the undetectable effect on uninfected cells supports this host protein as a potential new target for anti-HIV interventions.
BTK was originally identified as the mutated gene product in X-linked agammaglobulinemia (Tsukada et al. 1993; Vetrie . 1993) . BTK is a member of the Tec family of nonreceptor protein tyrosine kinases (PTKs), which is encompassed within the Src superfamily, an important regulator of lymphocyte signaling (Berg et al. 2005; Mano 1999 ). The enzyme has been widely characterized in B cells as an important regulator of development, differentiation, cell survival, and growth as part of a membrane-associated signalosome (Kurosaki 1997; Kurosaki 2000; Rawlings and Witte 1994; Uckun 1998) . Moreover, BTK was the first tyrosine kinase identified as a dual-function regulator of apoptosis in what may seem a cell type-specific function (Uckun 1998) . We have previously identified BTK as one of 17 proteins that are uniquely upregulated in the plasma membrane of HIV-1 latently infected T cells (Berro et al. 2007) . After viral activation in infected cells, there is a virus-specific redistribution of nuclear and cytoplasmic BTK to punctuated foci at the plasma membrane that does not occur in the absence of viral particle production. Of particular interest, Smith et al. (1994a) originally established Tec kinase expression in hematopoietic cells with the exception of plasma and T cells, where mRNA levels of BTK were below detection levels by the Northern blot. Generally, it is widely accepted that there is a minimal BTK expression in T lymphocytes (de Weers et al. 1993; Smith et al. 1994a; Smith et al. 1994b; Yu et al. 2008) , whereas higher expression is seen in myeloid cells, including monocytes, macrophages, neutrophils, and mast cells (Mohamed et al. 2009 ). Thus, the observed BTK upregulation in HIV-1-infected cells sheds a new light on the involvement of Tec kinase members in infection.
To further evaluate the status of BTK expression in HIV-1 infection, we explored expression of this protein in a variety of uninfected and infected HIV-1 target cells. We have shown upregulation of BTK expression and phosphorylation in HIV-1 chronically infected cells, as wells as in de novoinfected cells and monocytic cell models. Transient RNAiselective depletion of the enzyme in latently infected cells that have undergone viral reactivation indicated that downregulation of BTK resulted in increased detection of apoptotic markers, namely activated caspase 3 and cleaved PARP, and that infected cells were more susceptible to anti-BTK antibody. Treatment of a panel of uninfected and infected cells and monocytes with LFM-A13 or ibrutinib reflected a similar apoptotic phenotype of BTK antibody-treated cells, with infected cells generally being more sensitive to treatment. Importantly, LFM-A13 successfully inhibited viral replication on a post-transcriptional stage of the viral replication in vivo in a humanized animal model (data not shown). Collectively, our findings indicate that BTK is specifically upregulated in both HIV-1-infected T cells and macrophages and is associated with the plasma membrane of infected cells. We speculate that BTK is normally intracellular but may be associated with membrane (phosphorylated form) in infected cells, hence becoming accessible to antibody treatment.
The leflunomide metabolite analog LFM-A13 is a rationally designed specific inhibitor of BTK (Mahajan et al. 1999; Robak and Robak 2012) . Recently, a number of tyrosine kinase inhibitors became available for both preclinical and clinical trials including several BTK inhibitors such as LFM-A13, Fig. 8 Functional categories of LFM-A13-regulated phosphoproteins and signaling networks. Uninfected CEM and HIV-1-infected ACH2 cells were treated with DMSO or LFM-A13 for 24 h; cell lysates were prepared and analyzed with RPMA as described in BMaterials and methods.^Significantly altered proteins are listed in Table 1 (two-tailed t test, α≤0.05, n=3). A protein-protein interaction network was drawn by STRING 9.0 (http://string-db. org/) using proteins identified and data from SWISS-PROT function annotation as input GDC-0834, AVL-101, AVL-292, and PCI-32765 (Robak and Robak 2012) . Avila Therapeutics (AVL-292) and Pharmacyclics (PCI-32765) both have developed covalent BTK inhibitors that are currently in the clinical trial pipeline for treatment of various malignancies associated with BTK dysregulation. PCI-32765 or ibrutinib, a selective and irreversible inhibitor, has gained significant ground in clinical development and was being investigated in patients with B cell malignancies, and recently FDA approved, that includes chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B cell lymphoma, and multiple myeloma (Advani et al. 2013; Carmi et al. 2012; Harrison 2012; Robak and Robak 2012; Winer et al. 2012) . Moreover, the advancement of these compounds in phase I and II clinical trials could be useful towards cART complementation once their effects on HIV-1 infection have been further explored.
The exact mechanism by which BTK monoclonal antibody or small-molecule inhibitor induce apoptosis in HIV-1-infected cells is not yet clear. Previously, we have identified BTK enrichment in the membrane proteome of latently infected cells and also observed the accumulation of BTK in distinct foci of the cell membrane upon viral reactivation (Berro et al. 2007 ). As previously described, BTK contains a PH domain that targets it to the plasma membrane, allowing it to play a pivotal role in B cell signaling (Kurosaki 2000) . Interestingly, a recent study identified a lipid raft BCR signaling tuning mechanism regulated by differential post-translational modification (Schmidt et al. 2009 ), hinting towards the complex regulatory loops governing the BTK signalosome. This signalosome is believed to occur predominantly in the cholesterol and sphingolipid-rich lipid raft or caveolae environments, where additional signal-transducing molecules also assemble (Fruman et al. 2000; Guo et al. 2000; Vargas et al. 2002) . Once commenced, BTK signaling at the plasma membrane conveys the integration of cytoplasmic and nuclear events. For example, BTK and PLC-γ2 have been shown to play a critical role in the activation of nuclear factor-κB (NF-κB) after lipopolysaccharide stimulation of the Toll-like receptor (TLR) or B cell receptor (BCR) engagement (Bajpai et al. 2000; Horwood et al. 2003; Petro et al. 2000) , and NF-κB signaling is compromised in BTK deficiency (Yu et al. 2008) . Also, it has been shown that BTK-mediated B cell activating factor receptor (BAFF-R)-dependent activation of NF-κB promotes B cell survival (Shinners et al. 2007 ). NF-κB is a canonical transcription factor that plays an essential role in innate and adaptive immunity, and given its involvement in the HIV-1 viral life cycle, it is possible that HIV-1 is exerting BTK-mediated NF-κB regulation to fine tune cell survival outcomes of the infected cell as well as viral transcription. Moreover, two functional NF-κB binding sites located at the BTK promoter have been recently described (Yu et al. 2008) . These have been shown to function in a positive proteasome-dependent autoregulatory feedback mechanism that BTK uses to stimulate transcription from its own promoter. Therefore, increased BTK expression in infection may be directly linked to NF-κB availability in the presence of viral infection and T cell activation. Additionally, BTK has been shown to directly target other transcription factors including BAP-135, TFII-I, TFB, and BAM11, indicative of BTK's role in gene expression and regulation (Hirano et al. 2004; Kikuchi et al. 2000; Novina et al. 1999; Webb et al. 2000a; Webb et al. 2000b; Yang and Desiderio 1997) .
In this study, we have demonstrated using antibody, siRNA, or other inhibitor molecule that BTK positively regulates productive HIV-1 infection either by activating the infected cells or enhancing the release of virus from the infected cells. Nevertheless, other members of this family have been reported to also have a direct effect on HIV-1 replication (Prins et al. 2012; Readinger et al. 2008; Schiralli Lester et al. 2013) . For example, inducible T cell kinase (ITK), another member of the Tec family tyrosine kinase, induces HIV-1 replication by regulating multiple steps of viral life cycle such as T cell activation, actin polymerization/polarization, and virion assembly and release. Specifically, ITK has been shown to co-localize with HIV-1 Gag on the plasma membrane during virus release (Schiralli Lester et al. 2013 ). ITK has also been shown to be involved in inducing activation signals during the formation of virological synapse that enhances cell-to-cell spread of HIV-1 (Prins et al. 2012) . Future studies will focus on elucidating the mechanistic details regarding the importance of BTK and other Tec family members for HIV-1 infection and how targeting the overexpressed Tec tyrosine kinases could eliminate HIV-1 infection especially in the latently infected cells.
Materials and methods
Cell cultures and reagents
HLM-1 cells obtained from the AIDS Research and Reference
Reagents Program (NIH, Bethesda, MD, USA) were grown in DMEM supplemented with 10 % heat-inactivated fetal bovine serum (FBS), 1 % L-glutamine, and 1 % streptomycin/ penicillin (Gibco/BRL, Gaithersburg, MD, USA). HLM-1 cells are HeLa-T4+ cells containing one integrated copy of HIV-1 genome with a Tat-defective mutation at the first AUG of the Tat gene. In the absence of stimulation, HLM-1 is completely negative for virus particle production, and viral transcripts (unspliced) are completely absent (Berro et al. 2006; Guendel et al. 2013) . HLM-1 cells were stimulated with 2 mM sodium butyrate for viral induction. The HIV-1-infected human cells J1.1 and ACH2 and their uninfected counterparts Jurkat and CEM cells, as well as the infected monocytic U1 cells and the corresponding uninfected U937 cells, were cultured in RPMI-1640 medium supplemented with 10 % heat-inactivated FBS, 1 % L -glutamine, and 1 % streptomycin/penicillin . The uninfected B cells (BJAB) were also grown in the same media. The J1.1 cell line is a Jurkat E6.1 derivative chronically infected with HIV-1 (LAI strain) (Perez et al. 1991) . ACH2 T cells are also infected with the HIV-1 LAI strain. ACH2 and J1.1 cells contain a single integrated copy of the HIV-1 genome (Clouse et al. 1989) , whereas U1 cells harbor two copies (one wild type and one mutant) of the viral genome (LAV-1 strain) (Folks et al. 1987; Guendel et al. 2013) . Monocytic U937 and U1 cells were induced to differentiate into monocytederived macrophages (MDM) with 250 nM of PMA for 96 h. All cells were incubated at 37°C in the presence of 5 % CO 2 .
Therapeutic treatments
Antibodies against BTK (611116) and XIAP (610762) were purchased from BD Transduction Laboratories (San Diego, CA, USA) and anti-CD45 (H-130) antibody was purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Mouse monoclonal anti-BTK IgG antibody (clone 53/BTK from BD Biosciences) recognizes human BTK but does not cross react with ITK (Tec kinase family member). This antibody is also specific for human BTK as neither wild type nor BTK-deficient chicken B cells show any reactivity with this antibody (Douhan Iii et al. 2007) . Inhibition studies were always performed with fresh antibodies. Fifty thousand cells were plated per well in a 96-well plate and treated the next day with the appropriate antibody dilution to a final concentration of 1, 5, or 10 μg/ml. Antibodies against β-actin (C-11), caspase 3 (H-277), and PARP-1/2 (H-250) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The commercially available BTK inhibitor LFM-A 1 3 o r α -c y a n o -β -h y d r o x y -β -m e t h y l -N -( 2 , 5 -dibromophenyl)propenamide was obtained from Sigma (Saint Louis, MO, USA) and prepared as a 10 mM stock solution dissolved in DMSO. Ibrutinib was purchased from Selleckchem (Catalog #S2680).
Cell viability assay
Viability was assessed by the trypan blue exclusion method using a Neubauer counting chamber. Fifty thousand cells were plated per well in a 96-well plate and treated the next day with 1 and 5 μg of antibody against BTK. After 48 h, CellTiter-Glo (Promega, Madison, WI, USA) was used to measure viability following the manufacturer's recommendations. CellTiter-Glo is a luminescent assay used to measure cell viability by analyzing the ATP levels. The reagent was added to the wells (1:1 reagent:media) and incubated at room temperature for 10 min protected from light. The luminescence signal was recorded using the GloMax-Multi Detection System (Promega) ). The viable cell number was normalized with the control group and the results were expressed as relative cell viability.
Protein extracts and immunoblotting
Cells were washed with phosphate-buffered saline (PBS) and lysed in a buffer containing Tris-HCl pH 7.5, 120 mM NaCl, 5 mM EDTA, 0.5 % NP-40, 50 mM NaF, 0.2 mM Na 3 VO 4 , 1 mM DTT, and one tablet of complete protease inhibitor cocktail per 50 ml. Cell lysis was performed on ice for 30 min and before centrifugation (at 14,000 rpm) for 5 min at 4°C (Van Duyne et al. 2011) . For separating cytoplasmic and nuclear proteins, a differential salt extraction method was employed. First, cells were collected and washed twice with PBS w/out Ca 2+ and Mg
2+
. Cytosolic extracts were then prepared by resuspending cells in 80 μl buffer A (10 mM KCl, 10 mM MgCl 2 , 10 mM HEPES, 1 mM EDTA, 1 mM DTT, 0.5 % NP-40, 0.1 % PMSF, and one EDTA-free complete protease inhibitor tablet per 50 ml) and incubating for 10 min on ice. Samples were spun at 5000g for 5 min at 4°C and the supernatants saved as cytosolic extract (CE). The pelleted nuclei were washed with 200 μl of buffer A and spun at 5000g for 5 min at 4°C. The supernatants were removed and nuclei resuspended in 80 μl of buffer B (450 mM NaCl, 1.5 mM MgCl 2 , 20 mM HEPES, 0.5 mM EDTA, 1 mM DTT, 0.5 % NP-40, 0.1 % PMSF, and one EDTA-free complete protease inhibitor tablet per 50 ml) and incubated for 10 min on ice (Popova et al. 2010) . Samples were spun at 20,000g for 10 min at 4°C and supernatants saved as nuclear extract (NE). The protein concentration in the supernatant was determined with a Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). For separating cytoplasmic versus nuclear proteins, a differential salt extraction method was employed. Cell extracts were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on a 4-20 % Tris-glycine gel (Invitrogen, Carlsbad, CA, USA) and analyzed by WB using specific antibodies.
Reverse transcriptase activity assay For RT assays, supernatants from infected cells (10 μl) were incubated in a 96-well plate with RT reaction mixture containing 1× RT buffer (50 mM Tris-HCl, 1 mM DTT, 5 mM MgCl 2 , 20 mM KCl), 0.1 % Triton, poly(A) (10-20 U), oligo(dT) (10-20 U), and [ 2011) . RT activity was measured in a Betaplate counter (Wallac, Gaithersburg, MD).
RNA extraction and RT-PCR
Humanized mice were treated with LFM-A13 post-and preinfection with dual-tropic HIV-1 89.6 virus. Total RNA was isolated from the infected mouse PMBCs using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. Five hundred nanograms of total RNA was used to generate complementary DNA (cDNA) with the iScript cDNA Synthesis Kit (Bio-Rad) using oligo-dT reverse primers ). The HIV-1 LTR and env genes were amplified by RT-PCR using primers specific for LTR and env as previously described Zhou et al. 2004) .
RT reaction and quantitative PCR
For quantitative analysis of HIV-1 RNA, total RNA was isolated from culture supernatants of HIV-1-infected cells at different time points. RNA was purified using TRIzol Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. A total of 0.5 μg of RNA from the RNA fraction was treated with 0.25 mg/ml DNase I RNase-free (Roche, Mannheim, Germany) for 60 min in the presence of 5 mM MgCl 2 , followed by heat inactivation at 65°C for 15 min. A 200-500-ng aliquot of total RNA was used to generate cDNA with the GoScript Reverse Transcription System (Promega, Madison, WI) using oligo-dT reverse primer. Subsequent quantitative real-time PCR analysis was performed with 2 μl of undiluted and 10 −1 and 10 −2 diluted aliquots of RT reaction mixes. The iQ SYBR Green Supermix (Bio-Rad, Hercules, CA) was used with the primers specific for the HIV-1 gag gene: Gag1483-F (5′-AAGGGGAAGTGACATAGCAG-3′) and Gag1625-R (5′-GCTGGTAGGGCTATACATTCTTAC-3′) amplified 143-nt. fragment. Serial dilutions of DNA from 8E5 cells (CEM cell line containing a single copy of HIV-1 LAV provirus per cell) were used as the quantitative standards. Real-time PCR reactions were carried out at least in triplicate using the CFX96 Real-Time PCR System (Bio-Rad) and SFX Manager Software ver. 2.0.
Transfection assays
For siRNA-mediated knockdown of BTK, HLM-1 cells were transfected with 10 nM of double-stranded duplex HsBTK2 (BTK #1) or HsBTK3 (BTK #2), FlexiTube siRNA (SI00001029, SI00001036), HP Validated siRNA (Qiagen, Valencia, CA, USA), or luciferase (Dharmacon, Lafayette, CO, USA) using HiPerfect Reagent according to the manufacturer's recommendations (Qiagen) in 24-well plates. HIV-1 proviral DNA construct pNL4.3 (5 μg) was also transfected in U937 and Jurkat cells using Effectene (Qiagen) according to the manufacturer's instructions (Jaworski et al. 2014 ).
Size-exclusion chromatography
Both uninfected U937 and infected U1 monocytic cells were washed with PBS without Mg 2+ and Ca 2+ and resuspended in lysis buffer (50 mM Tris-HCl pH 7.5, 120 mM NaCl, 5 mM EDTA, 0.5 % NP-40, 50 mM NaF, 0.2 mM Na 3 VO 4 , 1 mM DTT, and one complete protease cocktail tablet per 50 ml) and incubated on ice for 20 min, with gentle vortexing. Lysates were then centrifuged at 4°C at 10,000 rpm for 10 min, and protein concentration in the supernatants was determined using the Bradford protein assay (Bio-Rad, Hercules, CA, USA). For each cell line, 2.5 mg of protein was brought up to 1 ml total volume using chromatography running buffer (0.2 M Tris-HCl pH 7.5, 0.5 M NaCl, and 5 % glycerol). The lysates were run on a Superose 6 10/300 size-exclusion chromatography column (GE Healthcare Bio-Sciences, Uppsala, Sweden) using the ÄKTA Purifier system (GE Healthcare Bio-Sciences, Piscataway, NJ, USA) . A quarter-inch gap was introduced to the top of the Superose 6 column to better separate small molecular weight complexes from fractions eluting off the far right side of the chromatogram. After sample injection (using a 1-ml loop), running buffer was set at a flow rate of 0.3 ml/min, and 0.5-ml fractions of the flow-through were collected at 4°C for a total of approximately 60 fractions. Every fifth fraction was acetone precipitated (∼250 μl) using four volumes of ice-cold 100 % acetone, incubating for 15 min on ice. Precipitates were centrifuged at 4°C for 10 min at 14, 000 rpm, supernatants were removed, and the pellets were dried for about 10 min at 95°C . The pellets were resuspended in Laemmli buffer and analyzed by immunoblotting with BTK (BD Biosciences) and actin antibodies (Santa Cruz).
Cell cycle analysis and apoptosis Cells were washed with PBS and fixed with 70 % ethanol. Following rehydration in PBS, cells were stained in PBS containing 25 μg/ml propidium iodide (Sigma, Saint Louis, MO, USA), 10 μg/ml RNase A (Sigma), and 0.1 % NP-40. Cells were analyzed on a BD FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). Acquisition was done with CELLQuest software, and cell cycle analysis was performed with ModFit LT software (Verity Software House, Topsham, ME, USA). Aggregates and debris were excluded by gating on the FL2W and FL2A parameters. The gates were at channel 200 for FL2 width versus FL2 area, with a doublet discriminator. Apoptosis was considered to be the population of cells localized in sub-G 1 area.
Surface staining of BTK and FACS analysis
For each cell line analyzed, 5 ml of culture (5×10 5 -cell/ml starting density) was incubated in T25 flasks at 37°C in 5 % CO 2 . For the U937 and U1 cell lines, two cultures were maintained either with or without 50 nM PMA stimulation. After 48 h of incubation, cells were counted and then 5×10 5 cells from each cell line were pelleted. Next, cells were resuspended in 100 μl of PBS+0.1 % bovine serum albumin (BSA) plus α-BTK mouse monoclonal antibodies (equal parts BD Transduction (Cat# 611116) and Santa Cruz Biotechnology (Cat# sc-28387)) and incubated on ice for 30 min. Two cell pellets, one Jurkat and one U937, were incubated with PBS+ 0.1 % BSA alone to serve as negative controls for nonspecific secondary antibody binding. Cells were then washed with 2 ml of cold PBS+0.1 % BSA and resuspended in 100 μl of PBS+0.1 % BSA plus FITC-labeled α-mouse secondary antibody and incubated on ice for 30 min in the dark. Cells were washed again and resuspended in 100 μl of PBS+0.1 % BSA plus 100 μl of 2 % paraformaldehyde. FACS analysis was then carried out using a FACSCalibur (BD Biosciences) and data analyzed using CellQuest software (BD Biosciences).
Reverse phase microarray
Approximately 30 nl of each sample (equivalent to 40 lysed cells) was arrayed onto nitrocellulose slides (Whatman, MA) by direct contact printing using a high-resolution 2470 arrayer (Aushon Biosystems, Billerica, MA). Samples were printed as duplicates of an 8.2-fold dilution series (Popova et al. 2010) . The linear range of each dilution curve was then used for quantitative comparisons between samples. Slides were stored at −20°C prior to detection. To estimate the total protein amount in each spot, several randomly selected slides were stained with Sypro Ruby Protein Blot Stain (Molecular Probes, Eugene, OR) and visualized on a Fluorchem imaging system (Alpha Innotech, San Leandro, CA). Slides were stained on a Dako Autostainer with specific antibodies using a biotin-linked peroxidase-catalyzed signal amplification (Dako, CSA kit). Specifically, the arrayed slides were placed into Re-Blot solution (Chemicon, Temecula, CA) for 15 min, washed twice in PBS 5 min each, placed into I-Block solution (Applied Biosystems, Foster City, CA) in PBS with 0.1 % Tween-20 for at least 2 h, and then immunostained using an automatic slide stainer (Autostainer, Dako Cytomation) and the manufacturer-supplied reagents (Popova et al. 2010) . Briefly, the slides were incubated for 5 min with hydrogen peroxide, rinsed with high-salt Tris-buffered saline (CSA buffer, Dako) supplemented with 0.1 % Tween-20, blocked with avidin block solution for 10 min, rinsed with CSA buffer, and then incubated with biotin block solution for 10 min. After another CSA buffer rinse, a 5-min incubation with protein block solution was followed by air-drying (Popova et al. 2010 ). The slides were incubated with either a specific primary antibody diluted in Dako antibody diluent or with only diluent as a control, for 30 min. Every antibody underwent extensive validation ensuring a specific detection of the antigenic protein as a single band on the Western blot of cell lysate. The slides were washed with CSA buffer and incubated with a secondary biotinylated goat anti-rabbit IgG antibody (1:7500) (Vector Labs, Burlingame, CA) for 15 min. Slides were incubated with diaminobenzidine chromogen diluted in Dako diaminobenzidine diluent for 5 min, washed in deionized water, and imaged using a Umax PowerLook III scanner (Umax, Dallas, TX) at 600 dpi. The images were analyzed with software AlphaAse FC (Alpha Innotech) (Popova et al. 2010) . For each antibody, the average pixel intensity value for the negative control (staining with secondary antibody only) was subtracted from the average pixel intensity value for the specific antibody and then normalized by the corresponding average value of the total protein intensity. Each sample dilution curve in each experiment was fitted with a nonlinear approximation equation and statistically evaluated using GraphPad Prism ver5 software (GraphPad Software, CA) (Popova et al. 2010) . All measurements were performed in triplicate. Data are represented as mean values with standard deviation (two-tailed t test, α=0.05, n=3).
Data analysis and bioinformatics
Quantitative data were analyzed by two-way ANOVA (OriginPro v. 8.0) and Student's t test (Microsoft Excel). Standard deviation was calculated in all quantitative experiments for at least three independent preparations. The difference was considered to be statistically significant when p≤ 0.05 (Iordanskaia and Nawshad 2011) . The function of the RPMA-identified proteins was elucidated by the SWISS-PROT database (http://www.expasy.org) and the interaction between the differentially expressed/modified proteins. A protein-protein interaction network was drawn by STRING 9.0 (http://string-db.org/) using proteins identified in this work and data from SWISS-PROT function annotation as input (Popova et al. 2010) .
